INTRODUCTION
The introduction of targeted anti-cytokine therapies with biologics is one of the major advancement in the treatment of inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC). 1 Treatments with biologics have been highly efficacious and have changed the natural history of the disease course in IBD.
Despite the undoubted efficacy of biological therapy, the economic burden on healthcare systems is considerable due to the extreme cost resulting from complexity of drug development and manufacturing processes. 2, 3 More than a decade has passed since the introduction of the first biological into clinical practice and many have reached or are close to patent expiration. This has led to the investigation and development of biosimilar drugs. 4 The U.S. Food and Drug Administration (FDA) defines a biosimilar as being a product that is highly similar to an already authorised biological with no clinically meaningful difference. 5 The introduction of biosimilars promises significant savings for health care systems. 6 Tumour necrosis factor (TNF)-a, which is produced by immune cells, is a key cytokine that drives inflammation in IBD. 7, 8 Many biological drugs that target TNF-a have been developed and are now increasingly used in clinical practice. 9, 10 Previous reviews suggested that biosimilars would be widely used for the treatment of IBD due to their cost savings and comparable efficacy. 11, 12 Recently, biosimilars of infliximab have been approved to treat adult and paediatric IBD patients. Biosimilars of infliximab, mainly because of their lower cost, have started to become commonly used in Asia and Europe. 13 Despite the growing availability of these products, only two meta-analyses have shown that there were no differences between biosimilar of infliximab and other biological agents in terms of clinical efficacy and safety in RA 14 and AS. 15 However, these studies only included one study of biosimilar of infliximab, and patients with IBD were not included in their analyses. Indeed, several systematic reviews about biosimilars have been recently published, 6, 16, 17 however, questions still remain about their comparability with the reference biologics in the treatment of IBD. 18, 19 In the present systematic review and meta-analysis, we aimed to assess the clinical efficacy and safety of biosimilar of anti-TNF-a agents in IBD.
MATERIALS AND METHODS
Data sources, search strategy and study selection We performed this study according to a priori defined protocol and in accordance with the PRISMA and MOOSE guidelines. 20, 21 The protocol of this meta-analysis has not been published or registered to any databases. We searched PubMed/MEDLINE, Google scholar, Scopus, EMBASE and Cochrane Central Register of Controlled Trials (inception to 1 May 2016) for studies assessing the efficacy and safety in patients with immune mediated diseases treated with biosimilar agents or those reference drugs. For Google scholar, only the first one thousand articles were reviewed at each search, as it does not provide results beyond it. We also searched abstracts from medical conferences (Digestive Disease Week, American College of Gastroenterology, European Crohn's and Colitis Organisation, and Advances in Inflammatory Bowel Diseases from 1 January 2004 to 1 May 2016) and bibliographies of identified articles for additional references.
To be eligible for inclusion, we considered randomised controlled studies (RCT) or observational studies evaluating the efficacy and safety of biosimilar of anti-TNF-a agents in patients with CD and UC. Studies required to report outcomes specifically for each disease. There were no restrictions regarding age, sex and duration of the study. We imposed no geographic or language restrictions and articles in languages other than English, Japanese or German were translated if necessary. Three authors (Y.K., A.Y. and F.K.) independently screened each of the potential titles, abstracts and/or full-manuscripts to determine whether they were eligible for inclusion. Areas of disagreement or uncertainty were resolved by consensus among the authors. The corresponding authors of studies were contacted to provide additional information on studies if required. Studies were identified with the terms "biosimilar*", "anti-TNF-a", "infliximab", "adalimumab", "etanercept", "golimumab", "certolizumab pegol", "inflammatory bowel disease", "Crohn's disease" and "ulcerative colitis" (both as medical subject headings and free text terms). These were combined using the set operator. The search strategy is described in Figure 1 .
Data extraction and quality assessment All data were independently extracted in duplicate by three authors (Y.K., A.Y. and F.K.) using a data extraction form. Data on the study characteristics, such as author name, year of publication, country, sample size, age of patients, comorbidity, outcome and incidence of adverse effects, were collected. The Cochrane Risk of Bias Assessment Instrument, 22 a scale that assesses the methodological quality of a clinical trial, was used to assess the quality of RCTs. The Newcastle-Ottawa Scale was used to assess the quality of the observational studies. 23 Star rating of 0-9 was allocated to each study based on three parameters [S, selection (0-4); C, Comparability (0-2); O, Outcome (0-3)]. Studies receiving six or more stars are considered of high quality.
24, 25
Outcome assessment The primary outcomes were the rates of clinical response, clinical remission and adverse events among patients with IBD treated with biosimilars of anti-TNF-a agents. The rates of clinical response and clinical remission were analysed separately by diseases at short (8-14 weeks) and medium term (24-30 weeks) . Among studies reporting outcomes in patients with IBD treated with biosimilars following transition from the reference biological, the rates of sustained clinical response and remission were analysed separately by diseases at short (16 weeks), medium (30-32 weeks) and long term (48-63 weeks) . The definitions of clinical response or remission, and sustained clinical response or remission of each study are shown in Table S1 and S2. Data were analysed separately for CD and UC.
Statistical analysis
Random-effects meta-analysis was performed to assess the efficacy and safety of biosimilars among patients with IBD. We evaluated the presence of heterogeneity across trials of each therapy using the I 2 statistic. I 2 < 25%
indicates low heterogeneity, 25-75% moderate heterogeneity, and >75% high heterogeneity respectively. 26 Statistic Q (Q) was also used with a probability (P) value of <0.10 as evidence of statistically significant heterogeneity. 27 We conducted subgroup meta-analyses or meta-regression to examine potential sources of heterogeneity, where indicated, with factors such as age, sex, disease duration, presence of perianal disease, previous exposure to anti-TNF agents, concomitant immunomodulator use, etc. To assess the potential for small-study effect and publication bias, we performed Begg's and Egger's test and constructed funnel plots to visualise possible asymmetry when 10 or more studies were available. [28] [29] [30] In addition, we conducted cumulative meta-analysis ranked by year to explore the robustness of the summary estimate. All statistical analyses were performed with Comprehensive Meta Analysis V2 (Biostat, Englewood, NJ, USA). P< 0.05 were considered statistically significant except for the Q statistic P value. All statistical tests were two-sided.
RESULTS

Study characteristics
We identified 8705 citations through literature search and excluded 8494 citations after initial screening of titles and abstracts. Eleven full text articles, including 829 patients were assessed for eligibility and included in our analysis ( Figure 1 ). No RCTs were found evaluating our outcomes. Among 11 observational studies, seven studies [31] [32] [33] [34] [35] [36] [37] were of CT-P13 (Remisima, Celltrion
Healthcare, Budapest, Hungary; Inflectra, Hospira Lake Forest, U.S.A.), a biosimilar of infliximab, in active IBD (including 7 CD and 6 UC reports). Six studies 33, 36, [38] [39] [40] [41] assessed the efficacy and safety of CT-P13
in maintaining clinical response in IBD following transition from infliximab (including 6 CD and 6 UC reports). Two studies included data on both induction and transition. We found no studies reporting outcomes in biosimilars of other biologics. All studies received 2-5 stars in the assessment by the NewcastleOttawa Scale. The characteristics and outcomes of the included studies [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] are summarised in Table 1, 2, and   Table S1 -S4. Meta-analysis of pooled rates of clinical response, clinical remission and adverse events with CT-P13 among observational studies There were four prospective and three retrospective observational studies 31-37 with a total of 552 patients with active IBD treated with CT-P13 included in our analysis ( Table 1) . Majority of the studies were among adult IBD patients. As shown in Figure Subgroup analysis according to age showed that the heterogeneity appeared to be due to the difference among subgroups as heterogeneity of each subgroup was lower (Table S5 ). Meta-regression showed a significant positive correlation between the proportion of males and clinical response, however, only five studies were included (data not shown). Small-study effects and publication biases were not analysed as there were only 4-6 studies which were inadequate to properly assess funnel plots. As shown in Figure 2b , the pooled rates for clinical remission at 8-14 weeks and 24-30 weeks among CD patients were 0.66 (95% CI = 0.53-0.77) and 0.60 (95% CI = 0.49-0.70) respectively. The pooled rates for clinical remission at 8-14 weeks and 24-30 weeks among UC patients were 0.50 (95% CI = 0.41-0.59) and 0.52 (95% that the heterogeneity appeared to be due to the difference among subgroups as heterogeneity of each subgroup was lower (Table S5) . Meta-regression also showed a significant positive correlation between the proportion of males and clinical remission, however, only six studies were included (data not shown). The heterogeneities of UC studies showed moderate heterogeneities at 8-14 weeks (I 2 = 33.4%, Q = 7.50, P = 0. 19) and at 30-32 weeks (I 2 = 59.3%, Q = 7.38, P = 0.061).
Subgroup analysis according to numbers of cohort showed that the heterogeneity appeared to be due to the difference among subgroups as heterogeneity of each subgroup was lower (Table S5) . Small-study effects and publication biases were not analysed as there were only 4-6 studies, which were inadequate to properly assess funnel plots. The pooled rates of overall adverse events, infusion reactions, latent tuberculosis, and infections among CD patients were 0.08 (95% CI = 0.02-0.26), 0.07 (95% CI = 0.03-0.16), 0.02 (95% CI = 0.01-0.06) and 0.02 (95% CI = 0.01-0.07) respectively ( Figure S1 ). Moderate heterogeneity was seen for overall adverse events regression was performed and there was a significant positive correlation between the proportion of patients with previous anti-TNF-a use and the risk of infusion reactions, however, only five studies were included (data not shown). Low heterogeneities were seen for latent tuberculosis and infections. Small-study effects and publication biases were not analysed as there were only 4-6 studies, which were inadequate to properly assess funnel plots. As shown in Figure S1 , the pooled rates for overall adverse events, infusion reactions, latent tuberculosis and infections among UC patients were 0.08 (95% CI = 0.03-0.17), 0.03 (95% CI = 0.01-0.08), 0.02 (95% CI = 0.01-0.05) and 0.03 (95% CI = 0.01-0.08) respectively. Low heterogeneities were seen for all adverse heterogeneity; I 2 <0.0001%, Q = 0.41, P = 0.82 heterogeneity; I 2 <0.0001%, Q = 0.11, P = 0.74 heterogeneity; I 2 = 0%, Q = 0, P = 1.00 heterogeneity; I 2 = 0%, Q = 0, P = 1.00 at 48-63 weeks; outcomes. Small-study effects and publication biases were not analysed as there were only 3-6 studies which were inadequate to properly assess funnel plots.
Meta-analysis of pooled rates of sustained clinical response, sustained clinical remission and adverse events among patients switching from infliximab to CT-P13 There were three prospective and three retrospective observational studies 33, 36, [38] [39] [40] [41] with a total of 277 IBD patients who switched to CT-P13 from infliximab (Table 2) . Majority of the studies were among adult patients. As shown in Figure 3a , CT-P13 demonstrated high rates of sustained clinical response at 30-32 weeks (0.85, 95% CI = 0.71-0.93) and 48-63 weeks (0.75, 95% CI = 0.44-0.92) among CD patients, however, it should be noted that the analysis at 48-63 weeks included only two studies. CT-P13 also demonstrated high rates of sustained clinical response at 30-32 weeks (0.96, 95% CI = 0.58-1.00) and 48-63 weeks (0.83, 95% CI = 0.19-0.99) among UC patients, though it should be noted that both of these analyses included only one study. Low heterogeneities were seen for all analyses among CD patients. Small-study effects and publication biases were not analysed as there were only two studies, which were inadequate to properly assess funnel plots.
As shown in Figure 3b , the pooled rates for sustained clinical remission at 16 weeks and 51 weeks among CD patients were 0.74 (95% CI = 0.55-0.87) and 0.92 (95% CI = 0.38-0.99), respectively, though it should be noted that each analysis included only two and one studies heterogeneity; I 2 = 62.0%, Q = 2.63, P = 0.10 heterogeneity; I 2 = 0%, Q = 0, P = 1.00 heterogeneity; I 2 = 0%, Q = 0, P = 1.00 heterogeneity; I 2 = 0%, Q = 0, P = 1.00 at 51 weeks; respectively. The pooled rates for sustained clinical remission at 16 weeks and 51 weeks among UC patients were 0.62 (95% CI = 0.42-0.78) and 0.83 (95% CI = 0.19-0.99), respectively, though it should be noted that both of these analyses included only one study. Moderate heterogeneity was seen at 16 weeks (I 2 = 62.0%, Q = 2.63, P = 0.10) among CD studies, which appeared as clinical heterogeneity to be influenced by the between study difference. There were not enough studies to construct funnel plots. The pooled rates for overall adverse events, infusion reactions, latent tuberculosis, and infections among CD patients were 0.10 (95% CI = 0.02-0.31), 0.04 (95% CI = 0.02-0.10), 0.03 (95% CI = 0.01-0.09), and 0.10 (95% CI = 0.03-0.26) respectively ( Figure S2 ). Low to moderate heterogeneities were seen for all adverse outcomes. Small-study effects and publication biases were not analysed as there were only 3-5 studies which were inadequate to properly assess funnel plots. As shown in Figure S2 , the pooled rates for overall adverse events, infusion related reactions, latent tuberculosis and infections among UC patients were 0.22 (95% CI = 0.04-0.63), 0.16 (95% CI = 0.07-0.32), 0.05 (95% CI = 0.02-0.17) and 0.08 (95% CI = 0.02-0.25), respectively. Low heterogeneities were seen for all adverse outcomes. Small-study effects and publication biases were not analysed as there were only 2-5 studies, which were inadequate to properly assess funnel plots.
Influence analysis and cumulative meta-analysis
Cumulative meta-analyses of each outcomes ranked by year were also performed ( Figure S3a-f) . All of the results of cumulative analyses were consistent with the aforementioned meta-analyses. We also undertook meta-analyses excluding studies with less than 10 patients when possible ( Figure S4a-f) . Each analysis showed almost no difference compared to the aforementioned results.
DISCUSSION
In the present study, we performed a systematic review and meta-analysis to assess the clinical efficacy and safety of biosimilar of anti-TNF-a agents, in patients with IBD. Meta-analyses of observational studies of CT-P13, a biosimilar of infliximab, showed high rates of clinical response and remission that persisted over a period of 1 year. Patients switching to CT-P13 from infliximab also demonstrated durable response. Risk of adverse events including infusion reactions and various infections appeared to be similar to those reported with infliximab. We found no RCTs, however, the results of our study support the use of CT-P13 in IBD.
We assessed the rates of clinical response, clinical remission and adverse events among patients with active IBD treated with CT-P13. We found 11 observational studies, but there were no RCTs in IBD. Furthermore, we found no studies with other biologics such as adalimumab, certolizumab pegol or golimumab. Among the seven observational studies including both CD and UC patients with active disease, CT-P13 demonstrated high rates of clinical response at 8-14 weeks (79% in CD, 74% in UC) and 24-30 weeks (75% in CD, 83% in UC), and low rates of overall adverse events (7% in CD, 8% in UC). Previous studies reported rates of clinical response with infliximab to be about 50-80%, [42] [43] [44] [45] [46] which is similar to the results of our analyses. Meanwhile, the analyses of six observational cohort studies of IBD patients switching from infliximab to CT-P13 indicated similar efficacy in maintaining response. The rates of clinical response at 30-32 weeks (85% in CD, 96% in UC) and 48-63 weeks (75% in CD, 83% in UC) appear to be comparable to the rates seen with infliximab. Recent literature suggests that an annual loss of response is observed in approximately 13% of patients on anti-TNF-a therapy 47, 48 and that most of these patients can be treated with increased doses or switching to another anti-TNF-a medication. However, data on switching from originator to biosimilar were limited and, in fact, the pooled rates for remission up to 16 weeks included only two studies for CD and one study for UC, and only one study each for CD and UC at week 51, both of which included small number of patients. In addition, included studies at each term were different, which likely contributed to the higher rates of remission at later time points after switching. Based on the results of our study, which included only limited number of studies and patient numbers, it would appear that switching from originator infliximab to CT-P13 is efficacious and safe. There were no studies that assessed outcomes of switching from a biosimilar agent to a reference agent, a situation that we might encounter in the near future. The pooled rates of adverse events were slightly higher among switching studies compared to that of nonswitching studies with the exception of infusion reaction in CD. However, these data of adverse events may have been affected by the reference agent which had been used prior to switching to CT-P13. Adverse events including anti-drug antibody formation may be affected by concomitant immunomodulator use, though majority of the studies did not provide enough information to analyse this. Our study has some limitations. At first, our analyses in IBD included only observational studies. A number of RCTs have shown similar outcomes with biosimilars of infliximab and etanercept in rheumatic diseases, 49, 50 however, there has been no RCT reported in IBD. Moreover, the qualities of the studies were mostly modest based on the Newcastle-Ottawa scale. There were only studies of CT-P13, a biosimilar of infliximab, and thus it remains unclear whether the results of our study can be applied to other biologics. The outcomes of our study included clinical response and remission, but their definitions in each study were not unified. Although it should be noted that the majority of clinical indices correlate well to each other. 51 Previous studies suggested that correlation of several indices allowed the development of disease activity thresholds, 52 but majority of studies included in our analysis lacked objective markers of disease activity such as faecal calprotectin, simple endoscopic score for Crohn's disease, and Mayo endoscopic score, which are now commonly used in RCTs. There were some baseline variability in patient population among the different studies, including in terms of previous exposure to anti-TNF-a agents, which can influence response to therapy. Indeed, we undertook meta-regression for each analysis and found there were correlations with some of our results. These variability may also contribute to the heterogeneity that were seen in some of our analyses. There was one study which focused on fistulizing CD, which showed similar results as compared to luminal CD. To assess the potential for small-study effect (publication bias). We could not perform visual inspection of funnel plots as well as Begg's and Egger's tests to assess the potential for small-study effect (publication bias), because the numbers of studies were less than 10 for all analyses. 53 Similarly, the results of meta-regression need to be interpreted with caution due to the small number of studies. 22 The included studies did not provide data of drug levels or anti-drug antibodies, which is also if interest as immunogenicity is a major cause of loss of response with anti-TNF therapy. 54 In conclusion, this systematic review and meta-analysis showed that CT-P13, a biosimilar of infliximab, was effective and safe among IBD patients. Further studies are needed, but the results of our study support the use of CT-P13 in the treatment of IBD.
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